Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24739276 | 1.00 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3KLKB1 | |
| SCHEMBL24738566 | 0.92 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3KLKB1 | |
| SCHEMBL24739278 | 0.90 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3KLKB1 | |
| SCHEMBL29879413 | 0.90 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3KLKB1 | |
| SCHEMBL24740030 | 0.89 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29879349 | 0.89 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24738565 | 0.88 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3KLKB1 | |
| SCHEMBL24738567 | 0.87 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3KLKB1 | |
| SCHEMBL30997793 | 0.86 | KLKB1 (0.35) | SLC6A2SLC6A4SLC6A3KLKB1 | |
| SCHEMBL24737618 | 0.84 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |